StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report published on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of NASDAQ TTNP opened at $3.84 on Monday. Titan Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $14.80. The company has a 50 day simple moving average of $3.58 and a 200-day simple moving average of $4.73.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- How Investors Can Find the Best Cheap Dividend Stocks
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to trade using analyst ratings
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
